ABBV vs BMY
AbbVie Inc. and Bristol Myers Squibb Co., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | BMY |
|---|---|---|
| Revenue | $61.2B | $48.2B |
| Net income | $4.2B | $7.1B |
| Gross margin | 70.2% | 71.1% |
| Net margin | 6.9% | 14.6% |
| Return on equity | · | 40.5% |
| Diluted EPS | $2.36 | $3.46 |
| Dividend / share | $6.65 | $2.49 |
| Payout ratio | 275.8% | 71.5% |
| Free cash flow | $17.8B | $12.8B |
| Equity | $-3.3B | $18.5B |
| Net debt / equity | · | 1.87× |
| Current ratio | 0.67× | 1.26× |
| Revenue CAGR 5y | 6.0% | 2.5% |
| Profit CAGR 5y | −1.7% | · |
ABBV bills 1.3× the revenue of BMY, and BMY keeps more of each dollar of revenue as profit (14.6% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | BMY |
|---|---|---|
| FY2025 | $61.2B | $48.2B |
| FY2024 | $56.3B | $48.3B |
| FY2023 | $54.3B | $45.0B |
| FY2022 | $58.1B | $46.2B |
| FY2021 | $56.2B | $46.4B |
| FY2020 | $45.8B | $42.5B |
| FY2019 | $33.3B | $26.1B |
| FY2018 | $32.8B | $22.6B |
| FY2017 | $28.2B | $20.8B |
| FY2016 | $25.6B | $19.4B |
Bottom line
| Fiscal year | ABBV | BMY |
|---|---|---|
| FY2025 | $4.2B | $7.1B |
| FY2024 | $4.3B | $-8.9B |
| FY2023 | $4.9B | $8.0B |
| FY2022 | $11.8B | $6.3B |
| FY2021 | $11.5B | $7.0B |
| FY2020 | $4.6B | $-9.0B |
| FY2019 | $7.9B | $3.4B |
| FY2018 | $5.7B | $4.9B |
| FY2017 | $5.3B | $1.0B |
| FY2016 | $6.0B | $4.5B |
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$12,966,000,000 | ABBV |
| FY2024 | +$8,034,000,000 | ABBV |
| FY2023 | +$9,312,000,000 | ABBV |
| FY2022 | +$11,895,000,000 | ABBV |
| FY2021 | +$9,812,000,000 | ABBV |
| FY2020 | +$3,286,000,000 | ABBV |
| FY2019 | +$7,121,000,000 | ABBV |
| FY2018 | +$10,192,000,000 | ABBV |
| FY2017 | +$7,440,000,000 | ABBV |
| FY2016 | +$6,211,000,000 | ABBV |
| FY2015 | +$6,299,000,000 | ABBV |
| FY2014 | +$4,081,000,000 | ABBV |
| FY2013 | +$2,405,000,000 | ABBV |
| FY2012 | +$759,000,000 | ABBV |
| FY2011 | −$3,800,000,000 | BMY |
The higher-revenue side has changed between ABBV and BMY over this period. The gap has widened since the earliest year compared.
15 of 19 comparable fiscal years — a year missing data on either side is not counted.
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −7.7 pp | BMY |
| FY2024 | +26.1 pp | ABBV |
| FY2023 | −8.9 pp | BMY |
| FY2022 | +6.7 pp | ABBV |
| FY2021 | +5.4 pp | ABBV |
| FY2020 | +31.2 pp | ABBV |
| FY2019 | +10.5 pp | ABBV |
| FY2018 | −4.6 pp | BMY |
| FY2017 | +14.1 pp | ABBV |
| FY2016 | +0.0 pp | ABBV |
| FY2015 | +12.7 pp | ABBV |
| FY2014 | −3.9 pp | BMY |
The higher net margin has changed hands between ABBV and BMY over this period.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's net margin has been more volatile than ABBV's over the 12 comparable fiscal years — 13.7 percentage points of standard deviation against 6.4.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and BMY over these 12 fiscal years — ABBV led in 8 and BMY in 4.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than BMY's over the 8 comparable fiscal years — 45.0 percentage points of standard deviation against 20.1.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ABBV led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.